 JENA, Germany, May 12, 2021 GLOBE NEWSWIRE -- InflaRx Nasdaq: IFRX, a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial results for the three months ended March 31, 2021. 